Daily Temporal Associations Between Psychoactive Substance Use and MS Symptoms
This study investigates psychoactive substance use multiple sclerosis patients experience daily. Using ecological momentary assessment, it tracks symptom fluctuations and substance use patterns. Findings reveal complex, symptom-dependent relationships…
Ozone Smog and Increased MS Risk in Children: Environmental Insights
This study highlights the link between air pollution autoimmune neurological conditions and increased risk of multiple sclerosis in children. It adds to evidence that environmental factors like ozone exposure may trigger autoimmune diseases. Clinicians…
Wim Hof Method and Lifestyle Changes Reduce Inflammation in MS
The Wim Hof method inflammation MS study highlights lifestyle changes that reduce inflammation in multiple sclerosis. This approach combines cold exposure, breathing, and meditation. It offers promising complementary strategies for managing MS symptoms.
Scientists Zero In on CD29 Protein Marker as Key Driver of MS in New Study
The cd29 protein marker multiple sclerosis study highlights its role as a key driver of brain inflammation. This discovery could lead to improved biomarkers and targeted treatments. Researchers emphasize the importance of this protein in understanding MS…
Persistent and Debilitating Muscle Spasms | Utah Medical Cannabis Guidelines
Utah's spasticity clinical guidelines provide evidence-based protocols for medical cannabis use in persistent and debilitating muscle spasms. These guidelines help clinicians with dosing and delivery methods for spasticity management. Patients with…
Quantum Biopharma Seeks FDA Clearance for Lucid-MS Phase 2 Trial
Quantum Biopharma is advancing a cannabis-based therapeutic phase 2 trial for Lucid-MS. This trial targets cognitive symptoms in multiple sclerosis patients. The phase 2 trial is a critical step to evaluate efficacy beyond safety.
Gut Cells Prime T-Cells to Trigger Brain Inflammation in MS: Study Overview
This study highlights the gut-brain-immune axis connection as a key factor in multiple sclerosis pathology. Gut cells prime T-cells that trigger brain inflammation, revealing new therapeutic targets. Understanding this connection may improve personalized…
Over 70% of MS Patients in Rehab Take 5+ Medications, Study Finds
Polypharmacy in MS rehabilitation is a significant clinical challenge, with over 70% of patients taking five or more medications. This study highlights the potential for cannabis to consolidate therapies and reduce drug interactions. Understanding…
New Research Project Explores Menopause in Women with MS
Menopause multiple sclerosis research is uncovering how hormonal transitions affect disease progression and symptom management in women. This new study focuses on neuroinflammation and hormonal changes unique to women with MS during menopause.…
Honoring the Trailblazers with MS Who Changed Cannabis Policy
Multiple sclerosis cannabis advocacy has played a pivotal role in shaping medical cannabis policy. MS patients were among the first to demonstrate therapeutic benefits of cannabinoids in clinical settings. Their efforts helped establish evidence-based…